Meeting
2018 Gastrointestinal Cancers Symposium
A phase II trial of LEE011 in combination with everolimus in the treatment of advanced well differentiated neuroendocrine tumors of foregut origin.
Authors
Nitya Prabhakar Raj
Memorial Sloan-Kettering Cancer Center, New York, NY
Nitya Prabhakar Raj , Virginia Kelly , Jennifer A. Chan , A. Dasari , Marinela Capanu , Laura Tang , Diane Lauren Reidy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT03070301
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr TPS546)
DOI
10.1200/JCO.2018.36.4_suppl.TPS546
Abstract #
TPS546
Poster Bd #
R1
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus in patients with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial.
First Author: Eric Baudin
Poster
2016 ASCO Annual Meeting
Everolimus in combination with Octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 5-years update.
First Author: Emilio Bajetta
Poster
2013 ASCO Annual Meeting
Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.
First Author: Emilio Bajetta
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.
First Author: Michael J. Demeure